Salivary gland cancer research addresses a rare, histologically diverse group of malignancies with few approved systemic options, including emerging biomarker-driven and HER2-directed strategies.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
A prospective, non-randomized, two-cohort phase II trial (DISCOVARY) in 57 patients with androgen receptor (AR)-positive salivary gland carcinoma found that adding the LHRH agonist goserelin to the AR inhibitor darolutamide produced a substantially higher response rate than darolutamide alone, in a rare cancer with no approved systemic therapy.
A single-center, non-randomized phase 2 basket trial tested ado-trastuzumab emtansine (T-DM1) across five disease-specific cohorts of HER2-amplified solid tumors, asking whether a shared molecular driver predicts benefit from a HER2-targeted antibody-drug conjugate regardless of tumor origin.